This is a profile image of David Quigley

David Quigley

Senior PartnerNew York

Advises private equity and life sciences clients on strategy, transformation, mergers, acquisitions, joint ventures, and organization; serves biopharmaceutical, medtech and healthcare services companies

David is a global convener for our Private Equity & Principal Investors Practice. He is also a leader in our Life Sciences Practice in North America. He previously led the Life Sciences Practice’s commercial efforts around the world.

Over the last 20 years, David has advised private equity groups, portfolio companies, and publicly listed life-sciences companies on scores of transactions. As a leader in the private equity sector, he has personally led diligence efforts and supported major transformations in acquired companies, including mergers, integrations, and turnarounds. His client service areas cover commercial performance, corporate strategy—which includes mergers, acquisitions and joint ventures—and organization.

David also brings a unique view to his healthcare work. He has served a range of clients within this industry, including healthcare services companies, healthcare manufacturers, healthcare providers, and technology companies. In his work on commercial performance, David has served clients extensively on product launch efforts and has worked on several launches regarded in the industry as best-in-class. He has also supported clients recovering from launches that did not quite meet expectations. His experience covers a number of specialties including primary care and rare diseases.

In addition to his client commitments, David chairs the development committee of the board for the Center for Civilians in Conflict (CIVIC), an organization that works to protect civilians in times of war and conflict and prevent civilian harm.

Prior to joining McKinsey’s New York office in 1998, David held a variety of line management positions in the energy industry.

Published work

Perspectives on a slower era in private markets,” McKinsey & Company, March 2024

McKinsey Global Private Markets Review 2024: Private markets in a slower era, McKinsey & Company, March 2024

Private markets: A slower era,” McKinsey & Company, February 2024

Ten considerations for private markets in 2024,” McKinsey & Company, January 2024

The state of diversity in global private markets: 2023, McKinsey & Company, August 2023

Top trends in global private markets,” McKinsey & Company, May 2023

McKinsey Global Private Markets Review: Private markets turn down the volume,” McKinsey & Company, March 2023

The state of diversity in global private markets: 2022,” McKinsey & Company, November 2022

The state of diversity in US private equity,” McKinsey & Company, March 2022

A new portfolio model for biotech,” McKinsey & Company, January 2021

Genetic testing: Opportunities to unlock value in precision medicine,” McKinsey & Company, October 2018

The next act in healthcare private equity,” McKinsey & Company, December 2016

Past experience


Special projects



Queen’s University Belfast

University College Dublin